Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Saint Louis, Missouri 63104


Purpose:

Inclusion and exclusion criteria for fetal repair of MMC was established by the Management of Myelomeningocele Study (MOMS Trial) and these criteria are the standard of care throughout the United States. These criteria state exclusion for hypertension and diabetes which are known co-morbidities for obesity. Investigators plan to expand one exclusion criteria for open fetal repair surgery. Currently, an exclusion factor is a maternal BMI of 35.0 and greater.Investigators will maintain all other inclusion and exclusion criteria (including excluding for hypertension and diabetes) with the exception of expanding the BMI to include mothers with a BMI of 35.0 to 40.0. Co-morbidities of the research group will be compared to the comorbidities of the mothers published in the MOMS trial.


Study summary:

The MOMS trial proved prenatal repair of myelomeningocele was an advantage over postnatal repair for the fetus/neonate/child and is the standard of care for maternal/fetal dyads who meet the inclusion exclusion criteria. Investigators plan to maintain all inclusion exclusion criteria for open fetal repair surgery of myelomeningocele with one exception, the expansion of the maternal BMI to 40.0. This population of mothers with a BMI of 35.0 to 40.0 have not been studied. The morbidities of these mothers will be compared to morbidities of mothers with a BMI less than or equal to 34.9 currently in the scientific literature.


Criteria:

Inclusion Criteria: - Maternal BMI 35.0 to 40.0 - No maternal documented co-morbidities - Fetal MMC begins between thoracic 1 and sacral 1, on the spinal column. - Evidence of fetal hindbrain herniation (hindbrain is being pulled down the spinal column). - A gestational age is between 19 weeks 0 days and 26 weeks with evidence of placental membrane fusion. - Documented normal fetal karyotype. Exclusion Criteria: - History of maternal alloimmunization problem - Kell sensitization - Risk of preterm birth - History of spontaneous preterm birth - Cervix <20mm in length - Presence of cerclage - Placental problem - History of placental abruption - Placental Previa - Body-mass index of 40.1 or more - Maternal contraindication to surgery - Insulin-dependent pregestational diabetes - Hypertension or preeclampsia - HIV, hepatitis-B, or hepatitis-C positive - Other medical condition of risk to mother - Uterine problem - Previous hysterotomy in the active uterine segment - Severe fibroids - Uterine malformation (bicornuate, arcuate, unicornuate, didelphys) - No support person for periprocedural period - Inadequate support at home for pregnancy - Inadequate understanding of risks and benefits of fetal surgery - Inability to comply with medical restrictions, follow up after fetal surgery - Multiple gestation pregnancy (twins, triplets, etc.) - A fetal anomaly unrelated to myelomeningocele (heart defect, lung lesions) - Severe fetal kyphosis >30 degrees (curvature of the back)


NCT ID:

NCT02509377


Primary Contact:

Principal Investigator
Emanuel Vlastos, Associate Professor
St. Louis University


Backup Contact:

N/A


Location Contact:

Saint Louis, Missouri 63104
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.